Validation bottleneck persists in AI-driven healthcare

Only 0.2% of FDA-cleared AI medical devices have evidence for patient-centered outcomes, highlighting a gap between regulatory clearance and clinical utility. New articles emphasize the need for causal understanding and organ-on-a-chip platforms to bridge computational predictions and human biology.